Target
TIM-3
1 product, 1 indication
Indications
Advanced melanoma (1 products)
Loading...
1 drug
10 abstracts
Abstract
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors.Org: L&L Biopharma Co. LTD., Thoracic Cancer Institute, Tongji University School of Medicine,
Abstract
GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers.Org: Chang Gung Memorial Hospital at Linkou and Chang Gung University, Seoul National University Graduate School, AstraZeneca Global R&D (China) Co., AstraZeneca Pharmaceutical Co.,
Abstract
TRICK-MCC: A proof-of-concept, investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma.Org: University of Washington, Seattle, WA,
Abstract
A phase 1 study of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated (TAA) CD8+T cells in patients with advanced solid tumors.Org: Shanghai Cancer Center Fudan University,
Abstract
A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, a Cedars-Sinai Affiliate, Los Angeles, CA, Hackensack Meridian Health, Hackensack, NJ,
Abstract
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.Org: Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Chinese Academy of Sciences,
Abstract
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.Org: Moores Cancer Center, UC San Diego Health, University of California San Diego, La Jolla, CA, Institut Curie, Saint Cloud, France, Paris, France,
Abstract
Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer undergoing neoadjuvant chemotherapy: A comparison between patients with triple negative breast cancer (TNBC) and non-TNBC.Org: The Medical Oncology Centre of Rosebank, Johannesburg, South Africa, Department of Immunology, Faculty of Health Science, University of Pretoria, Pretoria, South Africa, University of Pretoria, Department of Immunology, Pretoria, South Africa, Netcare, City of Johannesburg, South Africa, Drs Gritzman and Thatcher Inc. Pathology Laboratory, City of Johannesburg, South Africa,
Abstract
Impact of area deprivation index on clinical outcomes of adults with acute myeloid leukemia at a rural academic medical center.Org: Dartmouth-Hitchcock Medical Center, Dartmouth Hitchcock Medical Center, Guarini School of Graduate Studies, Dartmouth College Geisel School of Medicine, The Dartmouth Institute,
Drug
cobolimab